NasdaqGM - Delayed Quote USD

Eton Pharmaceuticals, Inc. (ETON)

Compare
8.19 +0.19 (+2.37%)
At close: October 14 at 4:00 PM EDT
Loading Chart for ETON
DELL
  • Previous Close 8.00
  • Open 8.00
  • Bid 5.91 x 200
  • Ask 9.85 x 200
  • Day's Range 7.63 - 8.19
  • 52 Week Range 3.03 - 8.20
  • Volume 233,660
  • Avg. Volume 128,817
  • Market Cap (intraday) 211.598M
  • Beta (5Y Monthly) 1.31
  • PE Ratio (TTM) --
  • EPS (TTM) -0.26
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.50

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

www.etonpharma.com

30

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ETON

View More

Performance Overview: ETON

Trailing total returns as of 10/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ETON
86.99%
S&P 500
22.85%

1-Year Return

ETON
108.93%
S&P 500
35.40%

3-Year Return

ETON
50.83%
S&P 500
34.28%

5-Year Return

ETON
32.10%
S&P 500
97.28%

Compare To: ETON

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ETON

View More

Valuation Measures

Annual
As of 10/14/2024
  • Market Cap

    211.34M

  • Enterprise Value

    198.45M

  • Trailing P/E

    113.67

  • Forward P/E

    23.36

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.71

  • Price/Book (mrq)

    15.70

  • Enterprise Value/Revenue

    6.32

  • Enterprise Value/EBITDA

    51.26

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -21.31%

  • Return on Assets (ttm)

    -12.50%

  • Return on Equity (ttm)

    -44.30%

  • Revenue (ttm)

    31.38M

  • Net Income Avi to Common (ttm)

    -6.69M

  • Diluted EPS (ttm)

    -0.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.69M

  • Total Debt/Equity (mrq)

    36.23%

  • Levered Free Cash Flow (ttm)

    -380.25k

Research Analysis: ETON

View More

Company Insights: ETON

Research Reports: ETON

View More

People Also Watch